The expression of miR-130b-3p in the blood of patients with non-small cell lung cancer and its potential significance

doi:10.3969/j.issn.1009-976X.2022.06.004

Abstract

Abstract: Objective This research aims to explore the expression and potential clinical significance of miR-130b-3p in the blood of NSCLC patients. Methods The Cancer Genome Atlas, Gene Expression Omnibus, and Sequence Read Archive were used to download NSCLC-associated miRNAs expression data, then the expression data of miR-130b-3p was extracted from included datasets. Estimating standardized mean difference （SMD） to comprehensively present the expression level of miR-130b-3p in the blood of NSCLC patients. A diagnostic test was performed to explore the discriminated potential of differentially expressed miR-130b-3p between NSCLC patients and healthy people. By making an interaction for predicted results from 12 databases in miRwalk 2.0, we screened out the downstream target genes of miR-130b-3p. Enrichment analysis was used to find potential signaling pathways of miR-130b-3p downstream target genes in regulating NSCLC development. Results A total of 300 blood samples from seven studies were included. MiR-130b-3p is downregulated in blood of NSCLC patients, including both LUAD （SMD=-1.45,95%CI： -2.66~-0.23） and LUSC （SMD=-0.46, 95%CI：-0.84~-0.09）. The diagnostic test indicated miR-130b-3p has a good potential to discriminate NSCLC patients from healthy people AUC=0.85,95%CI：0.82~0.88）. Forty-seven genes are identified as miR-130b-3p downstream targets, they significantly enrich in Renin-angiotensin system pathway. Conclusion MiR-130b-3p is downregulated in the blood of NSCLC patients and is expected to be used for early screening of NSCLC.

Key words: microRNA, MiR-130b-3p, non-small cell lung cancer, blood

摘要： 目的探讨miR-130b-3p在NSCLC患者血液中的表达水平及潜在临床意义。方法本研究使用癌症基因组图谱（TCGA）、基因表达谱数据库（GEO）以及序列片段归档数据库（SRA）下载了NSCLC相关的miRNAs表达谱,并提取miR-130b-3p在各个纳入的数据集中的表达量。计算标准化均数差（SMD）综合展示miR-130b-3p在NSCLC患者血液中的表达水平,进行诊断试验以探讨差异表达的miR-130b-3p对NSCLC患者和健康人的鉴别潜力。通过对miRwalk 2.0中12个数据库的预测结果进行交集,筛选出miR-130b-3p的下游靶基因,并采用富集分析探讨miR-130b-3p下游靶基因调控NSCLC的潜在信号通路。结果共7项研究的300例NSCLC患者血液样本被纳入。miR-130b-3p在LUAD（SMD=-1.45,95%CI：-2.66~-0.23）以及LUSC（SMD=-0.46,95%CI：-0.84~-0.09）这两种NSCLC患者血液中的表达水平较对照组明显下调。诊断试验提示miR-130b-3p具有良好的区分NSCLC患者和健康人的潜力（AUC=0.85：95%CI：0.82~0.88）。47个基因被鉴定为miR-130b-3p的下游靶基因,这些靶基因显著富集于Renin-angiotensin system通路。结论在NSCLC患者血液中表达下调的miR-130b-3p有望用于NSCLC的筛查。

关键词: 微小RNA, miR-130b-3p, 非小细胞肺癌, 血液

CLC Number:

R734.2

LI Jing-xiao, LI Guo-sheng, XU Yang, HE Rong-quan, ZHOU Hua-fu, KONG Jin-liang, CHEN Gang. The expression of miR-130b-3p in the blood of patients with non-small cell lung cancer and its potential significance[J]. Lingnan Modern Clinics In Surgery, 2022, 22(06): 547-554.

李靖霄, 李国盛, 徐阳, 何融泉, 周华富, 孔晋亮, 陈罡. MiR-130b-3p在非小细胞肺癌患者血液中的表达及潜在意义[J]. 岭南现代临床外科, 2022, 22(06): 547-554.

References

[1] Chen W, Zheng R, Baade P, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Siegel R, Miller K, Fuchs H, Jemal A.Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7-33.
[3] Siegel R, Miller K, Fuchs H, Jemal A. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[4] Evison M.The current treatment landscape in the UK for stage III NSCLC[J]. Br J Cancer, 2020, 123(Suppl 1): 3-9.
[5] Imyanitov E, Iyevleva A, Levchenko E.Molecular testing and targeted therapy for non-small cell lung cancer: Currentstatus and perspectives[J]. Crit Rev Oncol Hematol, 2021, 157: 103194.
[6] Chae Y, Chang S, Ko T, et al.Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)[J]. Sci Rep, 2018, 8(1): 2918.
[7] Hoy H, Lynch T, Beck M.Surgical Treatment of Lung Cancer[J]. Crit Care Nurs Clin North Am, 2019, 31(3): 303-313.
[8] Lu T, Rothenberg M.MicroRNA[J]. J Allergy Clin Immunol, 2018, 141(4): 1202-1207.
[9] Huang S, Xue P, Han X, et al.Exosomal miR-130b-3p targets SIK1 to inhibit medulloblastoma tumorigenesis[J]. Cell Death Dis, 2020, 11(6): 408.
[10] Liao Y, Wang C, Yang Z, et al.Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma[J]. Theranostics, 2020, 10(12): 5209-5224.
[11] Shui Y, Yu X, Duan R, et al.miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Deltalike 1 in breast carcinoma[J]. Gene, 2017, 609: 80-87.
[12] Fort R, Mathó C, Oliveira-Rizzo C, et al.An integrated view of the role of miR-130b/301b miRNA cluster in prostate cancer[J]. Expe Hematol Oncol, 2018, 7: 10.
[13] Yu X, Wang Z, Han C, et al.LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(13): 7203.
[14] Hu Y, Yan J.Aberrant expression and mechanism of miR-130b-3p/phosphatase and tensin homolog in nephroblastoma in children[J]. Exp Therapeutic Med, 2019, 18(2): 1021-1028.
[15] Zhang Y, Meng W, Yue P, Li X.M2 macrophage-derived extracellular vesicles promote gastric cancer progression via a microRNA-130b-3p/MLL3/GRHL2 signaling cascade[J]. J Exp Clin Cancer Res, 2020, 39(1): 134.
[16] Yu D, Zhong M, Wang W.Long noncoding RNA CASC15 is upregulated in non-small cell lung cancer and facilitates cell proliferation and metastasis via targeting miR-130b-3p[J]. Eur Rev Med Pharmacol Sci, 2021, 25(4): 1765.
[17] Guo Q, Yan J, Song T, et al.microRNA-130b-3p Contained in MSC-Derived EVs Promotes Lung Cancer Progression by Regulating the FOXO3/NFE2L2/TXNRD1 Axis[J]. Mol Ther Oncolytics, 2021, 20: 132-146.
[18] Ulivi P, Petracci E, Marisi G, et al.Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer[J]. J Clin Med, 2019, 8(2): 131.
[19] Schwarzenbach H, Nishida N, Calin G, Pantel K.Clinical relevance of circulating cell-free microRNAs in cancer[J]. Nat Rev Clin Oncol, 2014, 11(3): 145-156.
[20] Gilad S, Meiri E, Yogev Y, et al.Serum microRNAs are promising novel biomarkers[J]. PLoS One, 2008, 3(9): e3148.
[21] Yang X, Zhang Q, Zhang M, et al.Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer[J]. Int J Biol Sci, 2019, 15(8): 1712-1722.
[22] Ding H, Wen W, Ding Q, Zhao X.Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer[J]. Cancer Control, 2020, 27(1): 1073274820964783.
[23] Trakunram K, Chaniad P, Geater S, et al.Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer[J]. Cancer Biol Med, 2020, 17(3): 652-663.